


First Announcement

Targeted Protein Degradation 5 21st - 22nd October 2026

The Fielder Centre, Hatfield

Registration open!

Abstract submission open!



Abstract
Submission



#ProtDeg26

First Announcement

Confirmed Speakers

Alessio Ciulli, *University of Dundee*

Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact

Joshua Clark, *TRIMTECH Therapeutics*

Leveraging the Clustering-Based Activation Mechanism of TRIM21 to Degrade Pathological Protein Aggregates

Mattia Cocco, *AstraZeneca*

Degrader Antibody Conjugates: the good, the bad and the case studies

Peter Cossar, *University of Dundee*

Hijacking Protein Complexes: Induced Chemical Ubiquitination of 14-3-3 Complexes Enables Targeting of Non-Ligandable Proteins

Lindsay Evans, *ICR*

Unhooking the Hook: Optimisation of the Aurora A Targeting PROTAC JB170 to CCT400028, and in vitro Degradation Chemical Probe

Krista Goodman, *Larkspur Bio*

Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma

Lyn Jones, *Dana-Farber Cancer Institute*

Rewriting E3 Ligase Function: The Discovery and Development of Cereblon-Neofunctionalizing Molecular Glues

Suzanne O'Connor, *University of Dundee*

Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation

Markus Schade, *AstraZeneca*

AZD9750 and the new Rule-of-oral-PROTACs

Chris Tame, *Ternary Therapeutics*

A computational platform for the design of any molecular glue

Kristin Riching, *Promega*

Understanding How Cell Context and Intrinsic Factors Contribute to PROTAC Activity

